Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cabaletta Bio, Inc. (Nasdaq: CABA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, Cabaletta Bio uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and key developments in its RESET™ clinical program for rese-cel (resecabtagene autoleucel).
Investors reviewing Cabaletta Bio’s filings can find details on quarterly and annual financial performance, including research and development and general and administrative expenses, as well as information on public offerings used to fund clinical and commercial readiness activities. Current reports on Form 8-K often furnish press releases that summarize clinical data from the RESET-Myositis™, RESET-SSc™, RESET-SLE™, RESET-MG™ and RESET-PV™ trials, describe regulatory interactions with the U.S. Food and Drug Administration, and outline registrational cohort designs for rese-cel in specific autoimmune indications.
Filings may also discuss regulatory designations granted to rese-cel, such as Regenerative Medicine Advanced Therapy and Fast Track designations, and PRIME access from the European Medicines Agency, along with updates on chemistry, manufacturing and controls activities and collaborations, including the use of Cellares’ automated Cell Shuttle™ and Cell Q™ platforms for clinical manufacturing and quality control testing. These disclosures help readers understand how Cabaletta Bio is preparing for potential Biologics License Application submissions and future commercialization.
On Stock Titan, Cabaletta Bio’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the contents of lengthy reports, such as annual reports on Form 10-K or quarterly reports on Form 10-Q. Users can also monitor Form 8-K filings for material clinical, regulatory or financing events related to rese-cel and the broader CABA™ platform. This page is a resource for analyzing Cabaletta Bio’s regulatory history, financial condition and key milestones in its autoimmune-focused cell therapy programs.
Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.
Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.